Ajay Major

Assistant Professor of Medicine

University of Colorado School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ajay Major is an Assistant Professor of Medicine at the University of Colorado Denver School of Medicine. His research focuses on hematologic malignancies, with recent articles addressing treatment decision-making in Hodgkin lymphoma, outcomes in refractory patients, and advancements in measuring adverse events in clinical trials. Dr. Major's work contributes significantly to understanding patient-reported outcomes and the implications of treatment delays in large B-cell lymphomas.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (21)

Jamie Flerlage

Division Chief Pediatric Hematology/Oncology

University of Rochester Medical Center

UNITED STATES

Ajay Major

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Mortality after colorectal cancer among survivors of childhood cancer

Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era.

Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series.

SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies

DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas

International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Mixed-Methods Study of End-of-Life Experiences of Patients With Hematologic Malignancies in Social Hospice Residential Home Care Settings

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions.

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma

Phase 1/2 study of carfilzomib, pomalidomide, dexamethasone with and without daratumumab in relapsed multiple myeloma.

A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent

Collaborators (21)

Jamie Flerlage

Chan Yoon Cheah

Krzysztof Giannopoulos

Peter Riedell

James Godfrey

Mark Fiala

Jorge Florindez

Tadeusz Kubicki

Christine Smith

Wendy Leisenring

Eliza Hawkes

Kelly Melekis

colm keane

Lucie M. Turcotte

Lena Specht

Michael Slade

Lidia Usnarska-Zubkiewicz

Zhengming Chen

Tomasz Wrobel

Timothy Voorhees

Saarang Deshpande

Make your next move.